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Abstract
AIM: To confirm the efficacy and safety of beva-
cizumab/XELOX combination for the treatment of 
locally advanced or metastatic colorectal cancer (CRC) 
in Italy.
Prospective Study
Bevacizumab plus XELOX as first-line treatment of 
metastatic colorectal cancer: The OBELIX study
Lorenzo Antonuzzo, Elisa Giommoni, Davide Pastorelli, Tiziana Latiano, Ida Pavese, Domenico Azzarello, 
Michele Aieta, Ilaria Pastina, Francesca Di Fabio, Alessandro Bertolini, Domenico Cristiano Corsi, Selene Mogavero, 
Valentina Angelini, Mario Pazzagli, Francesco Di Costanzo
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METHODS: This multicentric, prospective, open-label 
study included patients with CRC previously untreated 
with chemotherapy. Patients were administered 
bevacizumab in combination with XELOX. The primary 
efficacy end-point was progression-free survival 
(PFS). Secondary end-points included time to overall 
response (TOR), duration of response (DOR), time 
to treatment failure (TTF) and overall survival (OS). 
The incidence and type of adverse events AEs and 
severe AEs were evaluated. Also, the mutational status 
of BRAF and KRAS was assessed by high resolution 
melting and direct sequencing, and quality of life (QoL) 
was measured by the EuroQoL EQ-5D questionnaire at 
baseline and at the last visit.
RESULTS: The intention-to-treat population included 
197 patients (mean age: 62.3 ± 9.9 years, 56.4% 
males). At baseline, 16/34 evaluable subjects (47.1%) 
harbored a KRAS and/or a BRAF mutation; the mean 
QoL index was 80.2 ± 14.3. First-line therapy was 
given for 223.7 ± 175.9 d, and after a mean follow-
up of 387.7 ± 238.8 d all patients discontinued from 
the study mainly for disease progression (PD, 45.4%) 
and AEs (25.4%). Median PFS was 9.7 mo (95%CI: 
8.4-10.5) and the median values for secondary end-
points were: TOR = 3.9 mo (95%CI: 2.6-4.7), DOR 
= 8.5 mo (95%CI: 7.3-10.3), TTF = 6.7 mo (95%CI: 
6.0-7.7) and OS = 23.2 mo (95%CI: 20.1-27.2). 
Patients carrying at least one lesion had a lower 
overall response rate (66.7% vs  88.9%) and a lower 
probability of achieving complete or partial response 
than those without mutations, but the difference 
in relative risk was not statistically significant (P  = 
0.2). Mean EQ-5D-3L raw index score significantly 
decreased to 74.9 ± 19.1 at the last visit (signed-rank 
test, P  = 0.0076), but in general the evaluation on QoL 
perceived by patients was good.
CONCLUSION: The efficacy of bevacizumab in 
combination with XELOX in terms of PFS in patients 
with aCRC or mCRC in Italy was confirmed, with 
acceptable toxicity.
Key words: Bevacizumab; Colorectal neoplasms; 
Chemotherapy; anti-Vascular endothelial growth factor; 
XELOX
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Combined with fluorouracil-based chemo-
therapy, bevacizumab significantly improved survival, 
compared to placebo, in previously untreated meta-
static colorectal cancer (mCRC) patients and in 
second-line treatment. In this perspective, the aim of 
this multicentric, prospective, open-label, single arm, 
non comparative study (the OBELIX study) was to 
confirm previous results on the positive outcome of 
bevacizumab/XELOX treatment in locally advanced CRC 
(aCRC) or mCRC patients in Italy. Our findings confirm 
the clinical benefit provided by bevacizumab plus 
XELOX in terms of proliferation-free survival, without 
the appearance of new areas of toxicity and an overall 
acceptable safety profile.
Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, 
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INTRODUCTION
Vascular endothelial growth factor (VEGF) is a 
common target for the inhibition of tumor growth and 
metastasis, as it plays a central role in angiogenesis 
within the tumor[1]. Bevacizumab, a humanized 
anti-VEGF antibody, in combination with different 
chemotherapy regimens, has been tested in several 
studies for the treatment of colorectal cancer (CRC). 
Combined with fluorouracil-based chemotherapy, 
bevacizumab significantly improved survival, compared 
to placebo, in previously untreated metastatic CRC 
(mCRC) patients and in second-line treatment[2,3]. 
The efficacy of XELOX (capecitabine and oxaliplatin) 
in combination with bevacizumab was studied in a 
factorial-design study, where patients with mCRC 
were randomized to XELOX vs FOLFOX-4, and 
subsequently to bevacizumab vs placebo[4]. The clinical 
benefit reported in this study did not fully satisfy 
expectations, likely due to the early discontinuation of 
bevacizumab[4]. The BEAT and BriTE trials confirmed 
the safety profile of bevacizumab in first-line mCRC 
patients receiving various chemotherapy regimens, 
namely FOLFOX, XELOX, FOLFIRI or capecitabine[5,6].
In this perspective, the aim of this multicentric, 
prospective, open-label, single arm, non comparative 
study (the OBELIX study) was to confirm previous 
results on the positive outcome of bevacizumab/XELOX 




This study is registered at ClinicalTrials.gov. The 
registration identification number is NCT00577031.
Patients were included in this single-arm, open-
label, multicentre, phase Ⅲb, prospective study if they 
were ≥ 18 years old, had histologically/cytologically 
proven diagnosis of CRC, chemotherapy-naïve 
metastatic disease and ECOG (Eastern Cooperative 
Oncology Group) performance status (PS) between 0 
and 1. Patients had a life expectancy of > 12 wk and > 
1 measurable lesion according to “Response Evaluation 
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Criteria In Solid Tumors”[7]. Patients provided written 
informed consent. This study was approved by the 
Independent Ethics Committee of each site.
Main exclusion criteria consisted of: radiotherapy 
to any site within 4 wk before the study, untreated 
brain metastases, history of central nervous system 
disease, non-healing wounds and evidence of bleeding 
diathesis or coagulopathy. Moreover, patients with 
uncontrolled hypertension, clinically significant cardio-
vascular disease, current or recent ongoing treatment 
with anticoagulants for therapeutic purposes, chronic 
treatment with high-dose aspirin (> 325 mg/d), 
treatment with any investigational drug within 30 d prior 
to enrolment, known allergy to any of the components of 
the study medications, other co-existing malignancies 
or malignancies diagnosed within the last 5 years, 
lack of physical integrity of the upper gastrointestinal 
tract, were excluded, as well as pregnant or lactating 
women, or of childbearing potential with either a 
positive or no pregnancy test at baseline and patients 
unwilling to practice contraception during the study.
Treatment
The planned treatment schedule was the oral 
5-fluorouracil pro-drug capecitabine in combination 
with oxaliplatin plus the humanized anti-VEGF antibody 
bevacizumab. After signing the informed consent, 
eligible patients received 21-d cycles according to 
the following scheme: bevacizumab 7.5 mg/kg and 
oxaliplatin 130 mg/m2 (both intravenously) every 
21 d on the first day and capecitabine 1000 mg/m2 
twice daily for 14 consecutive days and 7 d of rest. 
XELOX therapy was administered for no more than 8 
cycles (6 mo), while bevacizumab until progression of 
disease (PD). Second-line chemotherapy was at the 
investigator’s discretion.
Assessment
Baseline data included medical history, vital signs, 
results from physical examination, concomitant 
diseases, concomitant treatments, hematology and 
blood chemistry parameters, proteinuria, tumor 
evaluation and ECOG-PS.
The primary efficacy variable was progression-
free survival (PFS). Patients without an event were 
censored at the time of the last contact where the 
patient was known to be progression-free or alive. The 
secondary efficacy parameters were represented by: 
overall response rate (ORR), time to overall response 
(TOR) such as complete response (CR) or partial 
response (PR), duration of response (DOR), time to 
treatment failure (TTF), overall survival (OS), radical 
(R0) resection rate, KRAS and BRAF mutation status 
(high resolution melting and direct sequencing) and 
Quality of Life (QoL, measured by the EuroQoL EQ-5D 
questionnaire)[8]. Adverse events (AEs) were recorded 
and graded according to the “National Cancer Institute 
Common Toxicity Criteria” version 3.0. AEs related 
to treatment were recorded for up to 6 mo after the 
last dose of study drug (serious events indefinitely) 
and were followed up until they stabilized or returned 
to baseline status. AEs unrelated to treatment were 
recorded and followed up for 28 d after last study 
dose.
Statistical analysis
Since comparison with historic control seems not 
appropriate in a single-arm, open-label, multicentre, 
non comparative phase Ⅲ study.
The planned study enrollment of 200 patients was 
considered an appropriate sample size to allow the 
evaluation of 190 patients (considering a dropout rate 
of 5%), which would be sufficient to provide evidence 
for improved PFS compared to historic controls[9].
Both primary and secondary efficacy analyses 
were based on the intention-to-treat (ITT) population 
(at least one dose of study medication taken and 
at least one efficacy measurement at baseline 
available), and analyses on per-protocol population 
were considered as supportive. All “time-to-event” 
variables were presented in Kaplan-Meier survival plots 
and summarized by median and 95%CI. Descriptive 
statistics of the overall lesion response were provided 
by visit/tumor assessment. Absolute and relative 
frequencies of patients with KRAS and BRAF mutations 
were reported. QoL results were summarized by 
descriptive summary tables at baseline and over 
time, and changes from baseline were verified by an 
ANCOVA model. Descriptive statistics were applied to 
safety analysis, together with absolute and relative 
frequency of subjects with events. Statistical analysis 
was performed using SAS System for Windows version 
9.2 (SAS Institute Inc., Cary, NC, United States). All 
statistical tests were performed with a significance 
level α = 0.05.
RESULTS
Baseline characteristics
This study enrolled 205 patients from 34 centers 
across Italy between February 2008 and November 
2009. Baseline demographic and clinical characteristics 
are shown in Table 1. The ITT population consisted 
of 197 patients. All patients discontinued from the 
study and the main reasons were PD (45.4%) and 
the presence of AEs (25.4%). The vast majority of 
patients had a baseline ECOG-PS of grade 0 (80.7%). 
Hypertension and diabetes were among the most 
frequent medical conditions accounting for 41.1% 
and 10.2% respectively. Surgical resection of primary 
tumor occurred in 152 patients (77.2%), on average 
at 61.2 ± 10.2 years. The mean baseline EQ-5D-3L 
QoL raw index was 78.9 ± 15.4 (range: 32-98).
Patients underwent 9.2 ± 7.3 cycles of bevacizumab, 
5.9 ± 2.7 cycles of capecitabine and 5.9 ± 2.6 cycles 
of oxaliplatin. The number of patients without any 
Antonuzzo L et al . Bevacizumab/XELOX in advanced/metastatic CRC
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dose modification or interruption was 44 (22.3%), 68 
(34.5%) and 58 (29.4%) for bevacizumab, capecitabine 
and oxaliplatin, respectively.
Efficacy
Primary efficacy parameter: In the ITT population, 
median PFS was 9.7 mo (95%CI: 8.4-10.5) (Figure 1). 
Treatment discontinuation, for reasons other than PD 
or missing tumor assessment after baseline, occurred 
in 98 cases, therefore those patients were censored. 
The remaining 99 patients experienced the event of 
interest (PD or death) during the treatment period.
Secondary efficacy parameters: A summary of 
ORRs is reported in Table 2. Median OS was 23.2 mo 
(95%CI: 20.1-27.2) (Figure 2). Median values for 
the other secondary end-points were: TOR = 3.9 mo 
(95%CI: 2.6-4.7); DOR = 8.5 mo (95%CI: 7.3-10.3); 
TTF = 6.7 mo (95%CI: 6.0-7.7). During the study, 47 
patients underwent R0 surgery of metastases and 5 
patients had 2 surgical procedures, for a total of 52 ITT 
patients (26.4%). Summary of R0 resection rates are 
shown in Table 3.
Analysis of KRAS and BRAF mutation status 
revealed that 16 out of 34 patients (47.1%) whose 
tumor was evaluated had at least one gene alteration 
(Table 1): 13 patients (38.2%) carried a KRAS 
mutation, 2 patients (5.9%) had a BRAF mutation 
and 1 patient (2.9%) harbored both mutations. 
Compared to wild type (wt) patients, subjects with 
KRAS or BRAF mutations had a lower ORR: 66.7% 
vs 88.9%. Indeed, the estimate relative risk (RR = 
0.75) suggested that the probability of achieving a 
CR or PR as best overall response is lower for patients 
with gene alterations. However, RR was not found 
to be statistically significant (95%CI: 0.51-1.11, 
P = 0.2). Considering that all patients had ECOG-
PS 0-1, two potential prognostic factors have been 
Characteristic n  (%)1
Total recruitment 205 (100)
   ITT population  197 (96.1)
Age (yr)
   Median (range)      63 (34-80)
   mean ± SD 62.3 ± 9.9
Gender
   Males  111 (56.4)
   Females    86 (43.6)
ECOG-PS
   0  159 (80.7)
   1    38 (19.3)
   > 1 0 (0)
Site of primary tumor
   Colon (any region)  141 (71.6)
   Rectum    46 (23.4)
   Rectum + colon (any region)    8 (4.1)
   Unknown    2 (1.0)
Prior treatments (adjuvant or neo-adjuvant)
   Chemotherapy    49 (24.9)
   Radiotherapy    21 (10.7)
   None  148 (75.1)
N of metastases for each patient
   1  105 (53.3)
   2    72 (36.5)
   > 3    20 (10.2)
Site of metastases
   Liver  150 (76.1)
   Lung    70 (35.5)
   Lymph nodes    27 (13.7)
   Peritoneum  14 (7.1)
   Other 98 (48)
Stage at first diagnosis
   Local regional    75 (38.1)
   Metastatic  122 (61.9)
KRAS and BRAF  mutation status (34 evaluated)
   Wild Type (KRAS/BRAF)    18 (52.9)
   Mutated KRAS    13 (38.2)
   Mutated BRAF    2 (5.9)
   Mutated KRAS and BRAF    1 (2.9)
1Values reported as number of patients and, in parentheses, percentage 
on total number of patients, unless specified otherwise. ECOG-PS: Eastern 
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Figure 1  Kaplan-Meier plot of progression free survival in the intention-to-
treat population. Median PFS = 9.7 mo (95%CI: 8.4-10.5). PFS: Progression 
free survival.
Figure 2  Kaplan-Meier plot of overall survival. Median OS = 23.2 mo (95%CI: 
20.1-27.2).
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Table 3  Summary of R0 resection rates
Table 2  Overall response rate of the intention-to-treat 
population
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evaluated: number of metastatic sites (1 site vs > 1 
site) and alkaline phosphatase levels (≥ 300 UI/mL 
vs < 300 UI/mL). Three groups were obtained: group 
1 (n = 105, 53.3%) with only one site of metastasis, 
group 2 (n = 70, 35.5%) with more than one site 
of metastasis and alkaline phosphatase < 300 UI/L 
and group 3 (n = 14, 7.1%) with more than one 
site of metastasis and alkaline phosphatase ≥ 300 
UI/L. For 8 patients (4.1%) this data was missing. 
Median PFS was 9.9 mo (95%CI: 8.4-12.7), 8.5 mo 
(95%CI: 7.2-11.2) and 10.4 mo (95%CI: 7.9-13.2) 
in group 1, 2 and 3 respectively (log-rank test P value 
= 0.527), whereas median OS was 25.9 mo (95%CI: 
20.8-32.3), 19.9 mo (95%CI: 17.4-28.4) and 17.9 
mo (95%CI: 12.4-26.5, log-rank test P value = 0.149), 
respectively. No statistically significant difference 
among the three groups was detected in terms of PFS 
or OS, possibly due to the different number of patients 
included in each group.
QoL was assessed at baseline and during the last 
visit: using the prevalence approach, 114 patients 
were evaluable and the mean EQ-5D-3L raw index 
score changed from 80.2 ± 14.3 at baseline to 74.9 
± 19.1 at the last visit; using the “Last Observation 
Carried Forward” (LOCF) approach, 142 patients were 
evaluable and the mean EQ-5D-3L raw index score 
changed from 80.2 ± 14.4 at baseline to 76.3 ± 18.6 
at last visit. The decreasing evaluation of overall health 
during the study was statistically significant (signed-
rank test performed on difference values gave a P = 
0.0076 with prevalence approach and P = 0.0131 with 
LOCF approach).
Safety
Patients were exposed to first-line treatment for an 
average of 223.7 ± 175.9 d and were observed during 
follow-up for 387.7 ± 238.8 d.
Adverse events and deaths: The vast majority 
(94.4%) of the safety population experienced at 
least one AE. The majority of AEs were classified 
as “gastrointestinal disorders” (74.6%), “general 
disorders and administration site conditions” (58.9%), 
“nervous system disorders” (56.9%) and “vascular 
disorders” (32.0%). Serious AEs (SAEs) occurred in 
56 patients (28.43%). Most AEs were drug-related 
(90.9%). Overall, 87.3% of patients had at least one 
AE suspected as related to chemotherapy. Concerning 
AEs of grade 4 suspected to be chemotherapy-
related, 2 patients had “diarrhea”, 1 patient had 
“gastrointestinal disorders”, 1 patient experienced 
“vomiting” and 2 patients reported “asthenia”. Sixty-
one patients (31.0%) experienced at least one AE 
suspected to be related to bevacizumab. Concerning 
AEs of grade 4 related to bevacizumab, 1 patient 
had “intestinal perforation”, 2 patients “pulmonary 
embolism”, 1 patient had “hypertension” and 1 patient 
had “hypertensive crisis”. Sixteen patients (8.1%) 
experienced at least one AE suspected to be related to 
the combination of chemotherapy and bevacizumab: 
“nausea” in 1.5% of patients, vomiting, fatigue, 
asthenia and/or hypertension in 1.0% each. One 
patient had “cardio-respiratory arrest” with toxicity 
grade 4 suspected to be related to the combination of 
chemotherapy and bevacizumab.
One-hundred patients (50.8%) died during the 
course of the study. Six subjects (3.1%) prematurely 
discontinued the study due to death and 94 (47.7%) 
died during follow-up mainly due to progression of 
their colorectal cancer (86 patients). Three cases 
were considered as related to bevacizumab, whereas 
no relationship with study drugs was reported in the 
remaining 9 patients who died due to a SAE.
DISCUSSION
In patients with mCRC, chemotherapy is recommended 
n  (%)1
CR (best overall response) 10 (5.1)
PR   87 (44.2)
SD   55 (27.9)
CB (CR + PR + SD) 152 (77.1)
PD 13 (6.6)
No tumor assessment   32 (16.2)
Reason for surgery Residual disease n  (%)1
Curative
No (radical surgery) 26 (55.8)
Yes   7 (13.5)
Unknown 2 (3.9)
Not applicable 4 (7.7)
Palliative
No (radical surgery) 2 (3.9)
Yes 4 (7.7)
Unknown 2 (3.9)
Not applicable 1 (1.9)
Biopsy
Yes 1 (1.9)
Not applicable 1 (1.9)
Unknown
Unknown 1 (1.9)
Not applicable 2 (3.9)
Other
Yes 1 (1.9)
Not applicable 2 (3.9)
1Values reported as number of patients and, in parentheses, percentage on 
total number of patients. CB: Clinical benefit; CR: Complete response; ITT: 
Intention-to-treat; PD: Progressive disease; PR: Partial response; SD: Stable 
disease.
1Values reported as number of patients and, in parentheses, percentage on 
total number of patients who underwent R0 resection. Patients are counted 
only once in each row. Each patient could have more than one surgery 
during the study period.
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to reduce symptoms and prolong survival. Various 
combinations of chemotherapy and biological drugs are 
available for first-line treatment depending on patients’ 
features, disease characteristics and aim of therapy. 
The combination of chemotherapy with targeted agents 
as bevacizumab in molecularly unselected populations, 
and anti-EGFR cetuximab and panitumumab in RAS 
wt patients significantly prolonged survival in phase Ⅲ 
randomized trials[2,10,11].
Results from the present study confirm the efficacy 
of bevacizumab in combination with XELOX in terms of 
PFS of metastatic or locally advanced CRC patients. All 
secondary end-points of this trial confirmed previous 
results, although OS was slightly higher in our study 
compared to results presented by Saltz and coworkers 
(23.2 mo vs 21.3 mo)[4]. This particular finding was not 
unexpected, since one limitation of the study by Saltz 
was that patients rarely received bevacizumab until PD, 
but, rather, treatment in the presence of toxicities was 
discontinued as a whole, instead of selectively, as the 
protocol permitted. A recently published phase Ⅱ trial 
performed on elderly patients showed an even higher 
PFS (11.5 mo, 95%CI: 10.0-12.9)[12]. In contrast, in 
our study, bevacizumab was only discontinued after 
PD, which could explain the longer OS achieved.
We have no data on single patients treated with 
bevacizumab monotherapy until PD, after bevacizumab/
XELOX. OS is affected by treatment after first 
progression, but unfortunately no data are available 
about the later lines of chemotherapy, as in this 
study second-line therapies were at the investigator’s 
discretion according to local guidelines, and thus were 
not recorded in the study’s CRF. In Italy, during the 
study period (Februry 2008-November 2009), patients 
treated in first-line with fluoropyrimidine and oxaliplatin 
plus bevacizumab received mostly second-line therapy 
with fluoropyrimidine plus irinotecan, whereas the use 
of bevacizumab beyond progression was not allowed, 
nor the use of FOLFIRI plus aflibercept. Therefore, 
we can assume that patients enrolled in the present 
study did not receive anti-VEGF therapy beyond PD 
(TML strategy)[13]. In the same period, patients with 
KRAS wt (exon 2, codon 12 and 13) tumors were 
treated with FOLFIRI plus cetuximab in second line or 
with cetuximab or panitumumab monotherapy in third 
line. Unfortunately, the total number of patients with 
KRAS wt tumor is unknown and consequently also the 
number of patients hypothetically treated with anti-
EGFR antibody.
Main limitations of the present study were the 
lack of randomization and blinding, but since this was 
intended to be a confirmatory study, randomization and 
blinding would have been beyond the requirements of 
the study. Moreover, although the bevacizumab/XELOX 
combination has proven its efficacy in treating CRC 
patients, treatment prognostic markers are still needed. 
Further investigation is also warranted for selecting the 
optimal treatment duration and the role of bevacizumab 
in selected patients groups.
The exploratory analysis indicated a lower proportion 
of CR and PR as best overall response during first line 
treatment (66.7%) in patients with KRAS or BRAF 
mutation compared to wt patients (88.9%), even 
though the difference was not statistically significant. In 
patients with gene alterations, PFS and the incidence of 
PD or death were not significantly different compared to 
wt. This is in line with previous findings of an Australian 
group which evaluated the impact of KRAS and BRAF 
mutational status on outcomes following treatment with 
capecitabine alone or in combination with bevacizumab 
and mitomycin in aCRC. It was shown that KRAS 
status was neither prognostic for OS nor predictive 
of bevacizumab outcome in this set of patients[14]. 
Nevertheless, in our study, the lack of statistical 
significance could also be explained by the low number 
of patients.
The decrease on the judgment on overall health 
between last visit and baseline was highly expected, 
due to the nature of the disease, but in general the 
evaluation on QoL perceived by patients was good. 
Concerning safety, the incidence of bevacizumab-
related AEs in this study was as expected for this kind 
of patients and study treatment, and comparable to 
that of previous studies[2-6,15].
The number of metastatic sites involved, PS, WBC 
count and alkaline phosphatase were evaluated in 
multivariate analysis as factors that influenced both 
response rate and OS in aCRC patients treated with 
5-FU-based combinations[16]. Subsequently, Giacchetti 
et al[17] found that the number of sites, PS and 
alkaline phosphatase were independent prognostic 
factors. Saltz et al[18] reported that a normal lactate 
dehydrogenase level and a PS = 0 were predictive 
factors of improved PFS and OS. Also, hemoglobin 
levels of at least 11 g/dL and a normal WBC count 
were predictive for PFS and OS. Unexpectedly, an age 
of > 65 years was also associated with a longer PFS. In 
this study, however, the analysis of clinical prognostic 
factors did not find statistical differences among the 
three groups of patients identified on the basis of the 
number of metastatic sites and the values of alkaline 
phosphatase.
In conclusion, the present study achieved its primary 
objective of confirming previous positive PFS outcomes 
of bevacizumab/XELOX combination treatment in CRC 
patients in an Italian setting. Secondary safety and 
efficacy objectives were also achieved, confirming 
the usefulness of this treatment and its good overall 
tolerability profile.
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In metastatic colorectal cancer (CRC) different options are available as first-
line therapy and beyond, that provided benefit in terms of clinical outcomes. 
In particular, the combination of different fluorouracil-based chemotherapy 
regimens with the humanized anti-Vascular endothelial growth factor (VEGF) 
antibody bevacizumab led to prolongation of patient survival, likely due to the 
pivotal role played by angiogenesis in CRC.
Research frontiers
In Italy, at the time of this study, few options were available for patients with 
untreated locally advanced or metastatic CRC. Evidence pointed towards the 
use of the bevacizumab/XELOX combination as an effective and safe strategy, 
but data were lacking in this setting.
Innovations and breakthroughs
This multicentric, prospective, open-label, phase Ⅲb trial was designed as a 
confirmatory study of the efficacy and safety of front-line bevacizumab/XELOX 
in Italian patients with locally advanced or metastatic CRC. Indeed, the results 
confirm that this combination may provide a benefit in terms of progression-free 
survival in these patients, with an overall good safety profile.
Applications
Patients with untreated CRC may benefit from administration of bevacizumab 
plus XELOX, without suffering of particular toxicity.
Terminology
CRC is a malignancy of colon and rectum and it is often diagnosed in already 
advanced stage. As to date it remains the second leading cause of cancer 
death worldwide, it is crucial to develop therapeutic strategies able to cure 
these patients. Bevacizumab was the first biologic drug approved by Food and 
Drug Administration in combination with chemotherapy for the treatment of 
adults with CRC. The rationale relies on the importance of physiological VEGF 
production, known to sustain angiogenesis, which in turn favors tumor growth.
Peer-review
This paper is interesting and confirms the results of progression-free survival 
objectified in the Phase Ⅲ studies. The authors confirm previous results 
on the positive outcome of bevacizumab/XELOX combination treatment in 
patients with locally advanced or metastatic colorectal cancer in Italy. This is a 
meaningful research.
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